Enhanced local bioavailability of single or compound drugs delivery to the inner ear through application of plga nanoparticles via round window administration

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 5591-5601

  Cai, Hui ^a   Wen, Xingxing ^a   Wen, Lu ^a   Tirelli, Nicola ^b,c   Zhang, Xiao ^a   Zhang, Yue ^a   Su, Huanpeng ^a   Yang, Fan ^a   Chen, Gang ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b University of Manchester the Mill   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Inner ear administration; Local bioavailability; Nanoparticles; Perilymph; Poly(D, L lactide co glycolide acid)

Indexed keywords

COUMARIN; COUMARIN 6; FLUORESCENT DYE; GINSENOSIDE; GINSENOSIDE RB 1; GINSENOSIDE RG 1; NANOPARTICLE; NOTOGINSENOSIDE R1; PANAX NOTOGINSENOSIDE; POLYGLACTIN; SALVIANOLIC ACID B; TANSHINONE IIA; UNCLASSIFIED DRUG; COUMARIN DERIVATIVE; HERBACEOUS AGENT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

AREA UNDER THE CURVE; ARTICLE; COCHLEA FENESTRA; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; EMULSION; ENCAPSULATION; EVAPORATION; GUINEA PIG; IN VITRO STUDY; INNER EAR; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PERILYMPH; ROUND WINDOW ADMINISTRATION; SUSTAINED DRUG RELEASE; ANIMAL; BIOAVAILABILITY; CHEMISTRY; METABOLISM;

ANIMALS; BIOLOGICAL AVAILABILITY; COUMARINS; DRUGS, CHINESE HERBAL; GUINEA PIGS; LACTIC ACID; NANOPARTICLES; PERILYMPH; POLYGLYCOLIC ACID; ROUND WINDOW, EAR;

EID: 84914693600     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s72555     Document Type: Article

References (41)

1. Angelborg C, Hillerdal M, Hultcrantz E, Larsen HC. The microsphere method for studies of inner ear blood flow. ORL J Otorhinolaryngol Relat Spec. 1988;50(6):355-362.
2. Juhn SK, Rybak LP. Labyrinthine barriers and cochlear homeostasis. Acta Otolaryngol. 1981;91(5-6):529-534.
3. Inamura N, Salt AN. Permeability changes of the blood-labyrinth barrier measured in vivo during experimental treatments. Hear Res. 1992;61(1-2):12-18.
4. Juhn SK, Hunter BA, Odland RM. Blood-labyrinth barrier and fluid dynamics of the inner ear. Int Tinnitus J. 2001;7(2):72-83.
5. Mukherjea D, Rybak LP, Sheehan KE, et al. Current strategies for drug delivery to the inner ear. Expert Opin Drug Discov. 2011;6(5):491-505.
6. Wagner N, Cayé-Thomasen P, Laurell G, Bagger-Sjöbäck D, Thomsen J. Cochlear hair cell loss in single-dose versus continuous round window administration of gentamicin. Acta Otolaryngol. 2005;125(4):340-345.
7. Salt AN, Plontke SK. Principles of local drug delivery to the inner ear. Audiol Neurootol. 2009;14(6):350-360.
8. Liu H, Feng L, Tolia G, Liddell MR, Hao J, Li SK. Evaluation of intratympanic formulations for inner ear delivery: methodology and sustained release formulation testing. Drug Dev Ind Pharm. 2014;40(7):896-903.
9. Chen G, Zhang X, Yang F, Mu L. Disposition of nanoparticle-based delivery system via inner ear administration. Curr Drug Metab. 2010;11(10):886-897.
10. Paulson DP, Abuzeid W, Jiang H, Oe T, O’Malley BW, Li D. A novel controlled local drug delivery system for inner ear disease. Laryngo­scope. 2008;118(4):706-711.
11. Minor LB, Schessel DA, Carey JP. Meniere’s disease. Curr Opin Neurol. 2004;17(1):9-16.
12. Lefebvre PP, Staecker H. Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol. 2002;122(7):698-702.
13. Goycoolea MV. The round window membrane under normal and pathological conditions. Acta Otolaryngol Suppl. 1992;493:43-55.
14. Bjurstrom S, Slepecky N, Angelborg C. A histopathological study of the inner ear after administration of hyaluronan into the middle ear of the guinea pig. Acta Otolaryngol Suppl. 1987;442:62-65.
15. Du X, Chen K, Kuriyavar S, et al. Magnetic targeted delivery of dexamethasone acetate across the round window membrane in guinea pigs. Otol Neurotol. 2013;34(1):41-47.
16. Buckiová D, Ranjan S, Newman TA, et al. Minimally invasive drug delivery to the cochlea through application of nanoparticles to the round window membrane. Nanomedicine (Lond). 2012;7(9):1339-1354.
17. Pritz CO, Dudás J, Rask-Andersen H, Schrott-Fischer A, Glueckert R. Nanomedicine strategies for drug delivery to the ear. Nanomedicine (Lond). 2013;8(7):1155-1172.
18. Di Toro R, Betti V, Spampinato S. Biocompatibility and integrin medi­ated adhesion of human osteoblasts to PLGA copolymers. Eur J Pharm Sci. 2004;21(2-3):161-169.
19. Acharya S, Sahoo SK. PLGA nanoparticles containing various anti­cancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63(3):170-183.
20. Tamura T, Kita T, Nakagawa T, et al. Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope. 2005;115(11):2000-2005.
21. Ge X, Jackson RL, Liu J, et al. Distribution of PLGA nanoparticles in chinchilla cochleae. Otolaryngol Head Neck Surg. 2007;137(4):619-623.
22. Patel NR, Damann K, Leonardi C, Sabliov CM. Size dependency of PLGA-nanoparticle uptake and antifungal activity against Aspergillus flavus. Nanomedicine (Lond). 2011;6(8):1381-1395.
23. Chen YC, Hsieh WY, Lee WF, Zeng DT. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier. J Biomater Appl. 2013;27(7):909-922.
24. Zhang X, Chen G, Mu L. Research progress of novel dosage forms and pharmaceutical technologies for effective components of Danshen and Sanqi and their combination. Zhong Cheng Yao. 2011;33:1568-1570.
25. Guo G, Li B, Wang Y, et al. Effects of salvianolic acid B on pro­liferation, neurite outgrowth and differentiation of neural stem cells derived from the cerebral cortex of embryonic mice. Sci China Life Sci. 2010;53(6):653-662.
26. Qiao Z, Ma J, Liu H. Evaluation of the antioxidant potential of Salvia miltiorrhiza ethanol extract in a rat model of ischemia-reperfusion injury. Molecules. 2011;16(12):10002-10012.
27. Fujita K, Hakuba N, Hata R, et al. Ginsenoside Rb1 protects against damage to the spiral ganglion cells after cochlear ischemia. Neurosci Lett. 2007;415(2):113-117.
28. Lin XQ. Curative effect survey of compound root of red rooted salvia injection liquid treating sudden deafness. Anhui Yi Yao. 2001;5:175-176.
29. Huang ZP. Two cases of Danshen tablets and other drug for treatment of Ménière’s disease. Nei Moivgol Med J. 2005;3:227.
30. Gao D, Tang S, Tong Q. Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery. Int J Nano­medicine. 2012;7:3517-3526.
31. Fei X, Chen X, Liang G, et al. Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. J Drug Target. 2009;17(5):408-414.
32. Jain RA. The manufacturing techniques of various drug loaded bio­degradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475-2490.
33. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release. 2005;107(3):428-448.
34. Chen YF, Jaw I, Shiao MS. Determination and pharmacokinetic analysis of salvianolic acid B in rat blood and bile by microdialysis and liquid chromatography. J Chromatogr A. 2005;1088(1-2):140-145.
35. Han M, Fang XL. Difference in oral absorption of ginsenoside Rg1 between in vitro and in vivo models. Acta Pharmacol Sin. 2006;27(4):499-505.
36. Li Q, Wang Y, Feng N, Fan Z, Sun J, Nan Y. Novel polymeric nanopar­ticles containing tanshinone IIA for the treatment of hepatoma. J Drug Target. 2008;16(10):725-732.
37. Goycoolea MV. Clinical aspects of round window membrane perme­ability under normal and pathological conditions. Acta Otolaryngol. 2001;121(4):437-447.
38. Swan EE, Mescher MJ, Sewell WF, Tao SL, Borenstein JT. Inner ear drug delivery for auditory applications. Adv Drug Deliv Rev. 2008;60(15):1583-1599.
39. Juhn SK, Hamaguchi Y, Goycoolea M. Review of round window membrane permeability. Acta Otolaryngol Suppl. 1989;457:43-48.
40. He W, Horn SW, Hussain MD. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int J Pharm. 2007;334(1-2):173-178.
41. Kumar A, Chen F, Mozhi A, et al. Innovative pharmaceutical develop­ment based on unique properties of nanoscale delivery formulation. Nanoscale. 2013;5(18):8307-8325.